Medivir and CRT to develop novel ADAM8 inhibitors for cancer
This article was originally published in Scrip
Executive Summary
Sweden's Medivir and Cancer Research Technology (CRT), the charity Cancer Research UK's commercialization and development arm, are partnering to develop a new class of drugs targeting the cell surface protein ADAM8, which may have promise in the treatment of pancreatic cancer, among other tumor types.